BioSpace News Archive

Ribometrix, a biotechnology company developing small molecule therapeutics that modulate RNA biology, today presented preclinical data supporting the potential of its eIF4E inhibitors in Estrogen Receptor-positive (ER+) breast cancer at the annual San Antonio Breast Cancer Symposium (SABCS), held December 5-9, 2023, in San Antonio, TX.

Astellas Pharma US, Inc. (President: Mark Reisenauer, “Astellas”) today announced that the U.S. Food and Drug Administration (FDA) has approved CRESEMBA® (isavuconazonium sulfate), an azole antifungal drug, for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients.

Boston Medical Center (BMC), a national leader in the treatment of sickle cell disease for more than 50 years, announced today that it will offer the first-ever gene therapy treatment program for sickle cell disease that uses a type of novel genome editing technology.

A limited feasibility study presented at this year’s San Antonio Breast Cancer Symposium (SABCS) found that Seno Medical’s Imagio® Breast Imaging System using opto-acoustic/ultrasound (OA/US) shows promise in detecting vessel and oxygenation changes preceding tumor volume decrease in patients who are in a trajectory to achieve a tumor pathologic complete response (pCR).

The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.

Arcellx, Inc. (NASDAQ: ACLX) today announced new clinical data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel). Anito-cel utilizes a novel D-Domain BCMA binder that is compact and stable, which results in a drug product with a high proportion of CAR+ cells and high surface expression, potentially enhancing antigen binding and more efficient Multiple Myeloma cell killing.

Pharvaris (Nasdaq: PHVS) today announced the presentation of one oral session and two posters at the Global Allergy and Asthma Excellence Network (GA²LEN) Urticaria Centers of Reference and Excellence (UCARE) Conference, being held from December 7-9, 2023, at the Rebouças Convention Center in São Paulo, Brazil.

GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, announces its revised outlook for 2024 and reflects on recent progress.

Magnetic sensor specialist startup Neuranics has announced that it will launch a magnetic sensor development kit that will record the magnetic activity of the heart and wirelessly transfer this over Bluetooth for live 24/7 recording and analysis on a smartphone, tablet, or laptop.

FluoGuide A/S, a pioneer in the cutting-edge field of precision cancer surgery, announced the status of the exercised warrants, issued in connection with the directed share issue in July this year, raising SEK 12 million.